AMBS Stock, Amarantus BioScience Holdings Inc Information

Amarantus Bioscience Holdings AMBS is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS wholly owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase b ready small molecule indicated for Parkinson s disease levodopa induced dyskinesia, Alzheimer s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program ESS , a regenerative medicine based approach for treating severe burns with full thickness autologous skin grown in tissue culture that is being pursued by AMBS wholly owned subsidiary Cutanogen Corporation. AMBS wholly owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte derived neurotrophic factor MANF . MANF Therapeutics, Inc. is developing MANF based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard. AMBS also owns approximately . million shares of Avant Diagnostics, Inc. via the sale of its wholly owned subsidiary Amarantus Diagnostics, Inc. that occurred in May .